current
pauciti
inform
regard
molecular
pathogenesi
mani
high
consequ
pathogen
hcp
pose
direct
threat
public
health
secur
nation
intern
exampl
variola
viru
varv
etiolog
agent
smallpox
respons
million
human
fatal
centuri
prior
success
erad
may
mahalingam
et
al
follow
cessat
routin
vaccinia
viru
vacv
vaccin
signific
portion
global
popul
left
vulner
varv
result
signific
concern
regard
potenti
releas
varv
anoth
close
relat
orthopoxviru
monkeypox
viru
mpxv
increasingli
vulner
popul
fear
realiz
continent
us
follow
unintent
releas
mpxv
shipment
ghanaian
rodent
destin
exot
pet
trade
damon
concern
also
rais
due
increas
incid
mpxv
infect
within
africa
rimoin
et
al
hemorrhag
fever
virus
includ
ebola
viru
ebov
also
consid
global
health
concern
due
potenti
accident
introduct
highli
lethal
virus
endem
region
intent
manipul
bioterror
purpos
concern
exacerb
recent
report
case
marburg
viru
marv
tourist
return
uganda
netherland
center
diseas
c
prevent
timen
et
al
moreov
concern
regard
viru
spread
predominantli
rural
urban
area
recent
ebola
viru
diseas
outbreak
strengthen
concern
highli
lethal
virus
could
unintent
introduc
dens
popul
area
bhaumik
wasswa
subsequ
investig
demonstr
ebov
infect
pig
potenti
transmit
viru
laboratori
condit
interspeci
nonhuman
primat
intraspeci
manner
airborn
contact
transmiss
respect
kobing
et
al
weingartl
et
al
argu
increas
advanc
understand
pathogen
diseas
process
mediat
may
provok
develop
engin
pathogen
enhanc
virul
petro
et
al
lindler
et
al
end
enhanc
technic
capabl
character
host
pathogen
molecular
respons
cours
infect
critic
import
understand
microbi
pathogenesi
identifi
novel
target
therapeut
intervent
irf
frederick
provid
uniqu
capabl
combin
novel
molecular
biolog
approach
gross
patholog
analysi
medic
imag
clinic
core
function
enhanc
select
character
anim
model
hcp
fig
molecular
pathogenesi
mani
high
consequ
emerg
pathogen
remain
larg
uncharacter
despit
associ
health
risk
potenti
econom
critic
infrastructur
burden
associ
hcp
diseas
outbreak
whether
intent
unintent
inde
larg
proport
investig
hcp
pathogenesi
limit
global
survey
host
gene
express
viru
life
cycl
experiment
anim
infect
clinic
sampl
infect
patient
gupta
et
al
geisbert
et
al
rubin
et
al
towner
et
al
estev
et
al
hartman
et
al
exampl
ebov
particl
attach
entri
human
macrophag
result
induct
pro
inflammatori
mediat
includ
interleukin
il
il
tumor
necrosi
factor
tnf
demonstr
microarray
analysi
wahl
jensen
et
al
kash
et
al
also
demonstr
ebov
infect
human
hepatocyt
result
suppress
antivir
respons
yen
et
al
identifi
discern
differ
immun
respons
nonhuman
primat
nhp
treat
coagul
inhibitor
compar
untreat
anim
lethal
ebov
infect
model
connor
colleagu
also
demonstr
transcript
profil
lassa
viru
infect
result
earli
induct
interferon
respons
toll
like
receptor
mediat
signal
network
aerosol
expos
nhp
malhotra
et
al
analys
host
gene
express
mpxv
infect
alkhalil
et
al
rubin
et
al
demonstr
infect
result
global
suppress
host
gene
express
recent
comparison
orthopoxviru
modul
host
gene
express
program
cours
vitro
infect
report
bourquain
colleagu
demonstr
cellular
transcript
assay
unrespons
infect
cowpox
viru
cpxv
vacv
mpxv
bourquain
et
al
addit
host
respons
cpxv
vacv
mpxv
significantli
differ
suggest
virus
famili
like
adapt
particular
mechan
pathogenesi
limit
abil
infer
host
respons
viru
famili
individu
virus
rubin
et
al
also
investig
gene
express
program
vacv
mpxv
provid
first
map
pathogen
specif
respons
cours
infect
orthopoxvirus
studi
global
gene
express
inform
mani
question
remain
regard
molecular
pathogenesi
hcp
particular
consider
debat
whether
appropri
assess
biolog
respons
transcript
translat
post
translat
level
although
prolifer
variou
high
throughput
methodolog
provid
platform
assess
biolog
respons
level
associ
cost
expertis
requir
investig
mani
instanc
limit
applic
also
increas
appreci
mani
cellular
process
regul
independ
chang
transcript
translat
post
translat
modif
kinas
mediat
protein
phosphoryl
best
character
inde
virtual
signal
transduct
process
regul
kinas
mediat
protein
phosphoryl
independ
biolog
complex
prokaryot
eukaryot
hunter
support
dysregul
kinas
activ
implic
grow
number
human
malign
kinas
gene
map
diseas
loci
knuutila
et
al
testament
biolog
import
kinas
kinas
identifi
human
genom
human
genom
estim
human
proteom
modifi
kinas
mediat
phosphoryl
hunter
individu
kinas
activ
may
also
reliabl
predictor
function
cellular
chang
chang
gene
protein
express
consid
central
role
broad
cellular
process
growth
develop
metabol
innat
immun
arsenault
et
al
kindrachuk
napper
thu
increas
interest
character
quantifi
global
activ
state
host
kinas
kinom
addit
integr
system
biolog
approach
includ
pathway
represent
analysi
ora
provid
enhanc
capabl
identifi
event
ie
signal
network
individu
kinas
critic
diseas
progress
resolut
perspect
therapeut
design
develop
kinas
logic
drug
target
consid
regulatori
role
cell
process
conserv
catalyt
cleft
arsenault
et
al
testament
current
kinas
inhibitor
us
food
drug
administr
fda
licensur
encompass
indic
includ
cancer
rheumatoid
arthriti
myeloid
fibrosi
transplant
reject
continu
increas
number
enter
preclin
trial
addit
kinas
frequent
target
gene
class
cancer
therapi
second
g
protein
coupl
receptor
therapeut
target
cohen
hopkin
groom
kinas
inhibitor
employ
treatment
malign
divers
leukemia
gastrointestin
stromal
tumor
imatinib
druker
et
al
diabet
retinopathi
ruboxistaurin
dani
sheetz
atop
dermat
safingol
eglen
reisin
cerebr
ischemia
fasudil
yamashita
et
al
also
increas
impetu
consid
repurpos
fda
approv
kinas
inhibitor
use
anti
infect
therapi
associ
cost
move
new
drug
bench
bedsid
estim
billion
use
approv
kinas
inhibitor
novel
applic
entic
nation
institut
health
center
advanc
translat
scienc
ncat
recent
adopt
new
strategi
aim
repurpos
drug
pre
exist
fda
approv
treatment
addit
malign
allison
support
reev
et
al
demonstr
imatinib
abl
famili
kinas
inhibitor
promot
surviv
vacv
infect
mice
reduc
viral
dissemin
five
order
magnitud
although
imatinib
neglig
effect
vacv
yield
author
demonstr
releas
envelop
extracellular
viru
eev
inhibit
drug
treatment
vitro
vivo
subsequ
studi
author
demonstr
imatinib
provid
protect
lethal
vacv
infect
mice
deliv
prophylact
therapeut
reev
et
al
demonstr
similar
inhibitori
effect
imatinib
mpxv
varv
eev
releas
viral
spread
provid
evid
broad
antiorthopoxviru
effect
drug
napier
et
al
also
demonstr
anti
infect
activ
limit
orthopoxviru
famili
member
imatinib
reduc
bacteri
load
granulomat
lesion
number
ad
prophylact
therapeut
mous
model
mycobacteri
infect
interestingli
author
also
demonstr
coadministr
imatinib
either
rifampicin
rifabutin
act
synergist
reduc
mycobacteri
load
vivo
concern
remain
regard
applic
kinas
inhibitor
infecti
diseas
therapi
due
potenti
immunosuppress
effect
follow
prolong
therapeut
administr
howev
must
also
temper
appreci
kinas
inhibitor
treatment
hcp
infect
would
like
short
term
natur
patholog
variou
hcp
famili
member
associ
overactiv
innat
immun
system
thu
kinas
inhibitor
suppress
viral
replic
directli
indirectli
reduc
patholog
effect
associ
overactiv
innat
immun
may
offer
dual
purpos
short
term
andor
immedi
treatment
strategi
hcp
infect
increas
interest
character
global
role
kinas
kinas
mediat
signal
transduct
human
diseas
potenti
develop
novel
research
platform
purpos
jalal
et
al
also
appreci
evolutionari
conserv
kinas
respect
substrat
provid
opportun
appli
similar
methodolog
kinom
analysi
across
anim
multipl
anim
vitro
vivo
tradit
phosphoproteom
technolog
limit
confin
natur
technolog
requir
analys
well
rel
scarciti
phosphoryl
protein
within
given
protein
sampl
total
popul
individu
protein
contrast
investig
host
kinom
base
well
defin
conserv
enzymat
phosphoryl
event
seem
logic
altern
arsenault
et
al
incorpor
high
throughput
analys
base
kinas
mediat
phosphotransf
event
peptid
kinom
array
provid
function
mechan
character
modul
host
cell
signal
network
diseas
pathogenesi
cohen
hopkin
groom
kinom
array
util
principl
kinas
substrat
specif
dictat
residu
adjac
phosphoacceptor
site
kreegipuu
et
al
inde
applic
synthet
peptid
kinas
analysi
support
report
kinas
recogn
phosphoryl
linear
peptid
target
compar
vmax
km
valu
nativ
protein
zhu
et
al
thu
synthesi
short
linear
peptid
sequenc
follow
coval
linkag
solid
platform
glass
slide
provid
econom
viabl
high
throughput
platform
investig
host
kinom
respons
kindrachuk
napper
detail
review
regard
commonli
use
strategi
peptid
synthesi
coval
linkag
found
elsewher
houseman
et
al
jalal
et
al
peptid
array
compris
hundr
thousand
immobil
specif
peptid
target
kinas
report
perspect
kinas
target
select
public
avail
databas
phosphosit
wwwphosphositeorg
phosphoelm
phosphoelmeuorg
provid
manual
curat
literatur
base
phosphoryl
site
broad
select
protein
typic
kinom
array
analys
cellular
lysat
compar
sampl
infectedstimul
vs
uninfectedunstimul
appli
kinom
array
follow
phosphotransf
activ
kinas
cell
supernat
correspond
peptid
target
fig
although
use
gamma
phosphor
analys
limit
high
throughput
aspect
kinom
analysi
increas
concern
regard
radioact
wast
remov
particular
within
high
contain
laboratori
environ
incorpor
phospho
specif
fluoresc
stain
pro
q
diamond
phosphoprotein
stain
remov
constraint
addit
postimag
extract
kinom
array
data
hinder
lack
softwar
analysi
packag
suitabl
extract
kinom
array
data
remedi
li
et
al
develop
platform
integr
intellig
kinom
analysi
piika
pipelin
http
saphireusaskcasaphirepiikaindexhtml
kinom
array
data
analysi
piika
rel
degre
activ
phosphoryl
fold
chang
differ
experiment
condit
assign
base
user
select
compar
diseas
vs
normal
treat
vs
untreat
infect
vs
uninfect
etc
follow
data
extract
piika
subsequ
analysi
data
set
pathway
ora
databas
provid
comput
method
dissect
biolog
inform
kinom
array
data
identifi
repres
function
signal
network
pathway
within
kinom
data
set
public
avail
pathway
analysi
databas
innatedb
wwwinnatedbcom
lynn
et
al
kyoto
encyclopedia
gene
genom
kegg
kanehisa
goto
provid
mechan
perform
analys
commerci
avail
softwar
ingenu
pathway
analysi
softwar
suit
provid
altern
mechan
deriv
biolog
data
kinom
analys
recommend
review
khatri
et
al
ramanan
et
al
reader
depth
analys
subject
cessat
routin
vacv
immun
follow
declar
global
smallpox
erad
signific
portion
global
popul
left
vulner
varv
thu
concern
rais
regard
potenti
impact
outbreak
varv
viru
increasingli
vulner
popul
addit
increas
incid
mpxv
rimoin
et
al
lend
credenc
concern
highlight
import
design
develop
novel
antivir
therapeut
strategi
orthopoxviru
infect
mpxv
compris
two
distinct
clade
genet
clinic
geograph
distinct
central
african
mpxv
associ
case
fatal
rate
approxim
nonvaccin
individu
wherea
west
african
mpxv
viru
respons
outbreak
us
caus
fatal
jezek
et
al
anim
infect
model
multipl
anim
speci
demonstr
similar
differ
virul
virus
differ
mpxv
clade
sbrana
et
al
hutson
et
al
osorio
et
al
saijo
et
al
howev
littl
inform
regard
molecular
process
host
viral
respons
virul
differ
address
shortcom
employ
kinom
analysi
character
differenti
host
respons
virus
mpxv
clade
bowick
et
al
previous
employ
system
kinom
analysi
first
investig
compar
differenti
host
respons
virul
attenu
virus
investig
viru
pathogenesi
combin
kinom
analysi
pathway
ora
molecular
biolog
techniqu
demonstr
human
monocyt
west
african
mpxv
regul
growth
factor
apoptosi
mediat
host
cell
respons
compar
congo
basin
mpxv
result
confirm
fluoresc
activ
cell
sort
analysi
west
african
mpxv
infect
result
signific
increas
apoptosi
human
monocyt
compar
congo
basin
mpxv
also
identifi
subset
kinas
differenti
modul
two
mpxv
clade
includ
akt
chemic
inhibit
akt
phosphoryl
significantli
reduc
congo
basin
mpxv
viru
titer
wherea
west
african
mpxv
viru
yield
affect
although
west
african
congo
basin
mpxv
protein
share
amino
acid
sequenc
similar
differ
sequenc
local
protein
associ
modif
host
respons
liko
et
al
therefor
like
respons
differ
seen
kinom
result
mani
infecti
diseas
particular
mediat
hcp
larg
portion
knowledg
diseas
process
reli
gross
patholog
molecular
pathogenesi
data
extract
anim
model
diseas
regard
anim
model
employ
extens
investig
hcp
pathogenesi
well
identif
novel
therapeut
evalu
associ
efficaciestox
murin
model
employ
extens
examin
hcp
pathogenesi
due
rel
cost
limit
genet
background
thu
increas
experiment
reproduc
avail
analyt
reagent
recent
seok
et
al
report
genom
respons
laboratori
mice
acut
inflammatori
diseas
model
correl
poorli
human
patient
although
author
recogn
prior
studi
like
imped
inadequ
studi
design
data
set
like
mani
investig
also
hinder
assum
conserv
function
host
respons
human
nonhuman
anim
speci
moreov
rel
pauciti
therapeut
candid
translat
anim
model
approv
use
human
hackam
redelmei
recent
note
one
third
studi
translat
random
clinic
trial
one
tenth
therapeut
candid
acquir
fda
approv
van
der
worp
et
al
postul
actual
success
rate
like
much
lower
statist
deriv
base
public
high
impact
journal
thu
like
practic
solut
design
speci
specif
molecular
platform
annot
physiolog
process
speci
specif
fashion
guid
select
appropri
anim
host
diseas
model
basi
conserv
molecular
respons
human
refer
fda
anim
rule
servic
udohah
fad
administr
incorpor
conserv
molecular
respons
human
guid
anim
model
select
would
presum
increas
confid
studi
therapeut
diseas
human
clinic
studi
ethic
thu
design
speci
specif
kinom
array
seem
logic
approach
particular
speci
reagent
avail
scarc
napper
colleagu
demonstr
abil
creat
speci
specif
kinom
array
divers
organ
includ
human
cow
hors
arsenault
et
al
kindrachuk
napper
although
much
earli
design
speci
specif
kinom
array
guid
manual
sequenc
homolog
search
use
blast
improv
bioinformat
applic
provid
signific
improv
predict
phosphoryl
site
nontyp
speci
particular
manual
approach
peptid
target
design
time
consum
subject
limit
homologu
human
phosphoryl
site
trost
et
al
trost
et
al
recent
report
creation
dappl
http
saphireusaskca
softwar
pipelin
homolog
base
predict
phosphoryl
site
dappl
provid
autom
interfac
circumv
limit
manual
approach
peptid
target
predict
also
provid
mechan
increas
accuraci
predict
well
divers
speci
examin
fig
collabor
laboratori
design
kinom
peptid
array
multipl
anim
speci
interest
investig
high
contain
pathogen
abil
incorpor
routin
kinom
analysi
whether
perspect
host
pathogen
provid
mechan
identif
novel
biomark
diseas
character
molecular
pathogenesi
identifi
novel
target
therapeut
intervent
fig
irf
frederick
first
maximum
contain
facil
integr
common
medic
imag
modal
compar
medicinepatholog
clinic
core
servic
molecular
diagnost
within
maximum
contain
bsl
environ
within
irf
frederick
strateg
mission
manag
coordin
facilit
research
emerg
infecti
diseas
develop
vaccin
countermeasur
improv
medic
outcom
patient
regard
kinom
research
irf
frederick
provid
research
abil
tempor
character
function
cellular
respons
host
speci
high
consequ
pathogen
base
uniqu
blend
medic
imag
capabl
maximum
contain
laboratori
irf
frederick
provid
unpreced
capabl
verifi
biolog
relev
molecular
analys
vitro
vivo
integr
variou
medic
imag
modal
evalu
progress
diseas
singl
anim
kinom
analysi
provid
opportun
verifi
biolog
relev
molecular
respons
cours
diseas
therapeut
intervent
facilit
develop
medic
countermeasur
addit
investig
hcp
molecular
pathogenesi
limit
reagent
avail
nonhuman
anim
speci
design
develop
speci
specif
kinom
analysi
irf
frederick
provid
uniqu
opportun
character
molecular
respons
identifi
novel
target
therapeut
intervent
taken
togeth
envis
kinom
provid
opportun
inform
select
appropri
anim
model
best
mimic
human
molecular
diseas
well
ident
conserv
biomark
associ
increas
suscept
resist
infect
given
emerg
import
cellular
kinas
caus
indic
therapeut
target
diseas
seem
certain
ongo
effort
develop
tool
strategi
enabl
character
kinom
high
throughput
cost
effect
fashion
opinion
peptid
array
repres
practic
robust
approach
date
achiev
goal
although
outbreak
hcp
often
sporad
remain
seriou
global
health
concern
concern
exacerb
knowledg
gap
regard
hcp
molecular
pathogenesi
scarciti
therapeut
option
beyond
support
care
particularli
troubl
consid
recent
outbreak
sudan
viru
bundibugyo
viru
uganda
drc
albarino
et
al
sin
nombr
viru
california
center
diseas
c
prevent
recent
emerg
middl
east
respiratori
syndrom
coronaviru
de
groot
et
al
thu
inher
import
character
molecular
pathogenesi
identifi
potenti
therapeut
target
strategi
emerg
infecti
diseas
kinom
analysi
peptid
array
provid
high
throughput
mechan
investig
hcp
pathogenesi
arsenault
et
al
addit
introduct
system
approach
specif
mine
larg
data
set
provid
opportun
gain
biolog
perspect
kinom
data
li
et
al
due
complex
host
immun
respons
particularli
infect
diseas
progress
prudent
investig
tempor
respons
biolog
level
closest
function
phenotyp
kinom
analysi
satisfi
goal
monitor
activ
state
function
signal
network
may
also
provid
opportun
identifi
uniqu
molecular
signatur
biomark
way
signal
network
individu
kinas
broadli
conserv
across
variou
pathogen
particular
import
perspect
therapeut
treatment
strategi
identif
conserv
host
target
modul
multipl
hcp
would
provid
focus
target
design
develop
broad
rang
antivir
therapeut
taken
togeth
kinom
analysi
irf
frederick
provid
uniqu
opportun
compar
global
function
host
respons
variou
hcp
particular
kinom
research
program
irf
frederick
provid
uniqu
platform
investig
delic
molecular
interplay
host
pathogen
infect
within
bsl
environ
content
public
necessarili
reflect
view
polici
us
depart
health
human
servic
institut
compani
affili
author
jhk
perform
work
employe
tunnel
govern
servic
inc
subcontractor
battel
memori
institut
jk
jw
perform
work
employe
battel
memori
institut
prime
contract
niaid
contract
